Who
Edward T. Mathers
Director
Company insider
Files Form 4 as: Director, OnKure Therapeutics; Director and 10% owner, MBX Biosciences; Director, Trevi Therapeutics; Director, Rhythm Pharmaceuticals; 10% owner, Korro Bio; 10% owner, SpyGlass Pharma; Director and 10% owner, NeueHealth; Director, Senti Biosciences Holdings.
In numbers
- Trades disclosed
- 168
- Buys
- 6
- Sells
- 2
- Bought
- $64.6M
- Sold
- $1.3M
- Companies
- 17
- Companies where not an officer
- 16
- First trade
- 3 Feb 2006
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —4,199 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —4,199 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $2.3M207,100 at $11.11 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code P | $2.7M242,945 at $11.11 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code P | $2.7M242,945 at $11.11 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $2.3M207,100 at $11.11 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —4,198 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —4,198 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass PharmaMedical Devices | SEC FORM 4 Code C | —1,619,240 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass PharmaMedical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass PharmaMedical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —1,619,240 | filing |
News
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL SystemSGP · manilatimes.net · 19 Oct 2026BioLineRx (NASDAQ:BLRX) and Korro Bio (NASDAQ:KRRO) Head to Head SurveyKRRO · dailypolitical.com · 14 Oct 2026Contrasting BioLineRx (NASDAQ:BLRX) & Korro Bio (NASDAQ:KRRO)KRRO · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Edward T. Mathers; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.